Nihon Keizai Shimbun (Nikkei Newspaper) as Japan’s largest economic newspaper reported the status of stem cell research on Jan 6, 2015 and introduced MEDIPOST as the representative Korean company in this field.

Nikkei Newspaper reported the advancement into Japan by major global companies in stem cell field, at the headline article on the first page. Nikkei Newspaper presented MEDIPOST of Korea as one of the 3 major companies in stem cell field successful in advancing into Japan, together with Pluristem of Israel and Reneuron of U.K.

Nikkei reported on MEDIPOST that “MEDIPOST is progressing development in Japan on medicine ‘CARTISTEM^®’ which is the medicine the Korean FDA had already granted permission in Korea, and the company is targeting the Japanese market which is much larger that Korean market.”

MEDIPOST is taking preparatory steps for permission on ‘CARTISTEM^®’ in Japan, such as consultation with PMDA of Japan, in tandem with the Japanese Regenerative Machine Act that went into enforcement in November 2014.

MEDIPOST was also introduced at Yomiuri as the biggest Japanese comprehensive daily newspaper in November 2014, as the representative Korean stem cell company.